Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20300377 | 0.77 | MAPT (0.53) | POLBMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL21640205 | 0.76 | MAPT (0.40) | POLBMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL2248826 | 0.75 | ALDH1A1 (0.44) | MAPTALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL19877231 | 0.75 | ALDH1A1 (0.44) | MAPTALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL2250472 | 0.75 | ALDH1A1 (0.44) | MAPTALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL3430613 | 0.75 | MAPT (0.43) | MAPTALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3011888 | 0.74 | POLB (0.37) | POLBMAPTALDH1A1KDM4EMEN1 | |
| SCHEMBL5772842 | 0.72 | NPC1 (0.30) | KMT2A | |
| SCHEMBL4044055 | 0.72 | NPC1 (0.30) | KMT2A | |
| SCHEMBL27852285 | 0.69 | DPP4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | MERCK SHARP & DOHME CORP. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10414775-B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | CYP27A1, CYP7A1, CYP7B1 | POLB 3303/4885MAPT 3177/4885ALDH1A1 432/4885 |
| US-20190218224-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | POLB 3123/4885MAPT 2718/4885ALDH1A1 355/4885 |
| US-20190218223-A1 | COMPOUNDS USEFUL FOR ALTERING THE LEVELS OF BILE ACIDS FOR THE TREATMENT OF DIABETES AND CARDIOMETABOLC DISEASE | CYP27A1, CYP7B1, CYP7A1 | POLB 3332/4885MAPT 2906/4885ALDH1A1 334/4885 |
| US-10414774-B2 | Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease | CYP27A1, CYP7B1, SLC10A1 | POLB 3731/4885MAPT 3076/4885ALDH1A1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.